Sato Yoshihiko, Sasano Hitoshi, Abe Sumiko, Sandhu Yuuki, Ueda Shoko, Harada Sonoko, Tanabe Yuki, Shima Kyoko, Kuwano Tetsuya, Uehara Yuya, Inoue Takayoshi, Okumura Ko, Takahashi Kazuhisa, Harada Norihiro
Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Tokyo 113-8421, Japan.
Research Institute for Diseases of Old Ages, Juntendo University Faculty of Medicine and Graduate School of Medicine, Tokyo 113-8421, Japan.
Curr Issues Mol Biol. 2024 Oct 15;46(10):11425-11437. doi: 10.3390/cimb46100680.
The analysis of skin surface lipid-RNAs (SSL-RNAs) provides a non-invasive method for understanding the molecular pathology of atopic dermatitis (AD), but its relevance to asthma remains uncertain. Although dupilumab, a biologic drug approved for both asthma and AD, has shown efficacy in improving symptoms for both conditions, its impact on SSL-RNAs is unclear. This study aimed to investigate the impact of dupilumab treatment on SSL-RNA profiles in patients with severe asthma. An SSL-RNA analysis was performed before and after administering dupilumab to asthma patients requiring this intervention. Skin samples were collected non-invasively from patients before and after one year of dupilumab treatment. Although 26 patients were enrolled, an SSL-RNA analysis was feasible in only 7 due to collection challenges. After dupilumab treatment, improvements were observed in asthma symptoms, exacerbation rates, and lung function parameters. Serum levels of total IgE and periostin decreased. The SSL-RNA analysis revealed the differential expression of 218 genes, indicating significant down-regulation of immune responses, particularly those associated with type 2 inflammation, suggesting potential improvement in epithelial barrier function. Dupilumab treatment may not only impact type 2 inflammation but also facilitate the normalization of the skin. Further studies are necessary to fully explore the potential of SSL-RNA analysis as a non-invasive biomarker for evaluating treatment response in asthma.
皮肤表面脂质RNA（SSL-RNA）分析为理解特应性皮炎（AD）的分子病理学提供了一种非侵入性方法，但其与哮喘的相关性仍不确定。尽管度普利尤单抗这种被批准用于哮喘和AD的生物药物已显示出对这两种疾病症状改善的疗效，但其对SSL-RNA的影响尚不清楚。本研究旨在调查度普利尤单抗治疗对重度哮喘患者SSL-RNA谱的影响。对需要这种干预的哮喘患者在给予度普利尤单抗前后进行了SSL-RNA分析。在度普利尤单抗治疗一年前后非侵入性地收集患者的皮肤样本。尽管招募了26名患者，但由于收集方面的挑战，只有7名患者的SSL-RNA分析可行。度普利尤单抗治疗后，哮喘症状、加重率和肺功能参数均有改善。血清总IgE和骨膜蛋白水平降低。SSL-RNA分析显示218个基因的差异表达，表明免疫反应显著下调，尤其是与2型炎症相关的免疫反应，提示上皮屏障功能可能得到改善。度普利尤单抗治疗可能不仅影响2型炎症，还促进皮肤的正常化。需要进一步研究以充分探索SSL-RNA分析作为评估哮喘治疗反应的非侵入性生物标志物的潜力。
